The Function of extravascular coagulation factor IX in haemostasis.
CRM status
coagulation factor IX
collagen IV
extravascular factor IX
haemophilia
Journal
Haemophilia : the official journal of the World Federation of Hemophilia
ISSN: 1365-2516
Titre abrégé: Haemophilia
Pays: England
ID NLM: 9442916
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
revised:
07
03
2021
received:
09
02
2021
accepted:
09
03
2021
pubmed:
30
3
2021
medline:
25
9
2021
entrez:
29
3
2021
Statut:
ppublish
Résumé
The majority of clotting factor IX (FIX) resides extravascularly, in the subendothelial basement membrane, where it is important for haemostasis. We summarize preclinical studies demonstrating extravascular FIX and its role in haemostasis and discuss clinical observations supporting this. We compare the in vivo binding of BeneFIX Three mouse models of haemophilia were used: the FIX knockout as the CRM CRM status affects recovery and prophylactic efficacy. Prophylactic protection decreases ~5X faster in CRM Preclinical and clinical results support the interpretation that FIX plays a role in haemostasis from its extravascular location. We believe that knowing the CRM status of haemophilia B patients is important for optimizing prophylactic dosing with less trial and error, thereby decreasing clinical morbidity.
Substances chimiques
Factor IX
9001-28-9
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
332-339Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
White GC 2nd, Rosendaal F, Aledort LM, et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85:560.
Malec LM, Croteau SE, Callaghan MU, Sidonio RF Jr. Spontaneous bleeding and poor bleeding response with extended half-life factor IX products: a survey of select US haemophilia treatment centres. Haemophilia. 2020;26(3):https://doi.org/10.1111/hae.13943
Kleiboer B, Nielsen B, Ma AD, Abajas Y, Monroe DM, Key NS. Excessive breakthrough bleeding in haemophilia B patients on factor IX-albumin fusion protein prophylactic therapy: a single centre case series. Haemophilia. 2020;26(1): https://doi.org/10.1111/hae.13896
Stern DM, Drillings M, Nossel HL, Hurlet-Jensen A, LaGamma KS, Owen J. Binding of factors IX and IXa to cultured vascular endothelial cells. Proc Natl Acad Sci USA. 1983;80:4119-4123.
Heimark RL, Schwartz SM. Binding of coagulation factors IX and X to the endothelial cell surface. Biochem Biophys Res Commun. 1983;111:723-731.
Toomey JR, Smith KJ, Roberts HR, Stafford DW. The endothelial cell binding determinant of human factor IX resides in the gamma-carboxyglutamic acid domain. Biochemistry. 1992;31:1806-1808.
Cheung WF, van den Born J, Kuhn K, Kjellen L, Hudson BG, Stafford DW. Identification of the endothelial cell binding site for factor IX. Proc Natl Acad Sci USA. 1996;93:11068-11073.
Wolberg AS, Stafford DW, Erie DA. Human factor IX binds to specific sites on the collagenous domain of collagen IV. J Biol Chem. 1997;272:16717-16720.
Cooley B, Funkhouser W, Monroe D, et al. Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice. Blood. 2016;128(2):286-292.
Loeliger EA, Hensen A, Mattern MJ, Veltkamp JJ, Bruning PF, Hemker HC. Treatment of Haemophilia B with purified factor IX (PPSB). Folia medica neerlandica. 1967;10:112-125.
Cooley B, Broze GJ Jr, Mann DM, Lin FC, Pedersen LG, Stafford DW. Dysfunctional endogenous FIX impairs prophylaxis in a mouse hemophilia B model. Blood. 2019;133:2445-2451.
Gunay U. A clinical comparison of two commercial preparations of prothrombin complex. Proc Inst Med Chic. 1973;29:315.
Zauber NP, Levin J. Factor IX levels in patients with hemophilia B (Christmas disease) following transfusion with concentrates of factor IX or fresh frozen plasma (FFP). Medicine. 1977;56:213-224.
Poon MC, Lillicrap D, Hensman C, Card R, Scully MF. Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study. Thromb Haemost. 2002;87:431-435.
Melchiorre D, Linari S, Manetti M, et al. Clinical, instrumental, serological and histological findings suggest that hemophilia B may be less severe than hemophilia A. Haematologica. 2016;101:219-225.
Castaman G, Matino D. Hemophilia A and B: molecular and clinical similarities and differences. Haematologica. 2019;104:1702-1709.
Morfini M. Secondary prophylaxis with factor IX concentrates: continuous infusion. Blood Transfus. 2008;6(Suppl 2):s21-s25.
Pastoft AE, Lykkesfeldt J, Ezban M, Tranholm M, Whinna HC, Lauritzen B. A sensitive venous bleeding model in haemophilia A mice: effects of two recombinant FVIII products (N8 and Advate(®)). Haemophilia. 2012;18:782-788.
Gui T, Reheman A, Ni H, et al. Abnormal hemostasis in a knock-in mouse carrying a variant of factor IX with impaired binding to collagen type IV. J Thromb Haemost. 2009;7:1843-1851.
Matino D, Iorio A, Stafford D, Chan A. Enhanced FIX collagen IV binding shows improved hemostatic effects in a hemophilia B mouse model. Top abstract presentation, ISTH SSC Meeting Dublin; 2018.
Kavakli K, Smith L, Kuliczkowski K, et al. Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B. Haemophilia. 2016;22(3):381-388. https://doi.org/10.1111/hae.12878
Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013;369:2313-2323.
Berntorp E. Pharmacokinetics of plasma-derived and recombinant factor IX: using population pharmacokinetics with sparse sampling data needs further study. Haemophilia. 2013;19:805-807.
Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46:D1074-D1082.
Collins PW, Moss J, Knobe K, Groth A, Colberg T, Watson E. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX. J Thromb Haemost. 2012;10(11):2305-2312.
Peters RT, Low SC, Kamphaus GD, et al. Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood. 2010;115:2057-2064.
Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7:715-725.
Malec L, Croteau S, Callaghan M, Matino D, Friedman K, Sidonio R Jr. Spontaneous bleeding and poor bleeding response with extended half-life factor IX Products: a survey of select US and Canadian hemophilia treatment centers. Blood. 2019;134(Supplement_1):2407. https://doi.org/10.1182/blood-2019-126196
Lewis RM, Reisner HM, Chung KS, Roberts HR. Detection of factor IX antibodies by radioimmunoassay: effect of calcium on antibody-factor IX interaction. Blood. 1980;56:608-614.
Rallapalli PM, Kemball-Cook G, Tuddenham EG, Gomez K, Perkins SJ. An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B. J Thromb Haemost. 2013;11:1329-1340.
Briet E. Three problems of haemophilia B. PhD Thesis, University of Leiden; 1977.
Cheung WF, Hamaguchi N, Smith KJ, Stafford DW. The binding of human factor IX to endothelial cells is mediated by residues 3-11. J Biol Chem. 1992;267:20529-20531.
Mancuso ME, Lubetsky A, Pan-Petesch B, et al. Long-term safety and efficacy of rIX-FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B. J Thromb Haemost. 2020;18:1065-1074.
Pasi KJ, Fischer K, Ragni M, et al. Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B. Thromb Haemost. 2017;117:508-518.
Young G, Collins PW, Colberg T, et al. Nonacog beta pegol (N9-GP) in haemophilia B: a multinational phase III safety and efficacy extension trial (paradigm4). Thromb Res. 2016;141:69-76.
Santagostino E, Mancuso ME, Tripodi A, et al. Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J Thromb Haemost. 2010;8:737-743.
Jin DY, Zhang TP, Gui T, Stafford DW, Monahan PE. Creation of a mouse expressing defective human factor IX. Blood. 2004;104:1733-1739.
Stern DM, Knitter G, Kisiel W. In vivo evidence of intravascular binding sites for coagulation factor IX. Br J Haematol. 1987;66(2):227-232. https://doi.org/10.1111/j.1365-2141.1987.tb01303.x
Hoffman M, Colina CM, McDonald AG, Arepally GM, Pedersen L, Monroe DM. Tissue factor around dermal vessels has bound factor VII in the absence of injury. J Thromb Haemost. 2007;5:1403-1408.
Behrens DT, Villone D, Koch M, et al. The Epidermal basement membrane is a composite of separate laminin- or collagen IV-containing networks connected by aggregated Perlecan, but not by Nidogens. J Biol Chem. 2012;287:18700-18709.
Flood VH, Schlauderaff AC, Haberichter SL, et al. Crucial role for the VWF A1 domain in binding to type IV collagen. Blood. 2015;125:2297-2304.
Slobodianuk TL, Kochelek C, Foeckler J, Kalloway S, Weiler H, Flood VH. Defective collagen binding and increased bleeding in a murine model of von Willebrand disease affecting collagen IV binding. J Thromb Haemost. 2019;17:63-71.
Wong SS, Ostergaard S, Hall G, et al. A novel DFP tripeptide motif interacts with the coagulation factor XI apple 2 domain. Blood. 2016;127:2915-2923.